Need to find a common ground with Moderna and Johnson & Johnson for initiating vaccine supply : V K Paul

Discussions are still going on with Moderna and Johnson & Johnson vaccine manufacturers to start their vaccine supplies, though the government has given Emergency Use Authorisation (EUA) for these COVID-19 vaccines, said Dr Vinod K Paul, member of NITI Aayog.

It may be noted that the foreign vaccine manufacturers including Pfizer and Moderna have been seeking indemnity against any legal issues if the vaccine may create any serious adverse reactions.

Apprising the same in a weekly press briefing on COVID-19 developments in the country, Paul informed that the option for using EUA is open for both the companies. “With regard to their import or deployment from the production of Johnson and Johnson in the country, we have been informing you that there are issues around which we still have to find a common ground with respective vaccine manufacturers and we are working in that direction.”

Commenting on the vaccine administration in children, Paul said that Zydus Cadila’s vaccine has been approved for potential use in children.

“We have information on the stock pile and our scientific bodies are discussing how and when and where to. Covaxin trial is very close to completion of trials for children. Once we have results, that vaccine will be potentially available. Biological E has also been granted permission to complete the trial,” he said.

Health Secretary, Rajesh Bhushan, Ministry of Health and Family Welfare, said, “We are still witnessing the second surge. It is not over. Public health response should be on the basis that the second surge is not over though the cases are coming down.”

He urged the public to be careful while celebrating the upcoming festivals in the wake of the pandemic.

  • Related Posts

    Karnataka State Information Commission slaps ₹1 lakh penalty on BDA official for failing to provide information

    BENGALURU: Sending a strong message against officials who have made it a habit to ignore the applications under Right to Information (RTI) Act, the Karnataka Information Commission has cracked the…

    NSQ reporting nearly doubles in 2025, buoyed by greater state participation

    New Delhi: The number of drug samples declared as Not of Standard Quality (NSQ) by the drug regulators in the country has registered over two-fold growth during the 12 months of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Karnataka State Information Commission slaps ₹1 lakh penalty on BDA official for failing to provide information

    Karnataka State Information Commission slaps ₹1 lakh penalty on BDA official for failing to provide information

    NSQ reporting nearly doubles in 2025, buoyed by greater state participation

    NSQ reporting nearly doubles in 2025, buoyed by greater state participation

    Two Gyms In Firozabad Raided, Seize 20 Mephentermine Injections Amid Health Concerns

    Two Gyms In Firozabad Raided, Seize 20 Mephentermine Injections Amid Health Concerns

    Delhi Drugs Control Department Seizes Insulin Stock Worth Rs 20.06 Lakh

    Delhi Drugs Control Department Seizes Insulin Stock Worth Rs 20.06 Lakh

    Kerala Health Department Has Launched The MeHEALTH App

    Kerala Health Department Has Launched The MeHEALTH App

    War Could Affect Up To ₹5,000 Crore Of Pharma Exports And Disrupt Supply Chains

    War Could Affect Up To ₹5,000 Crore Of Pharma Exports And Disrupt Supply Chains